c11 methionine
Small moleculeexperimentalImaging agent
METHIONINE C-11 is a synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis. METHIONINE C-11 is produced without any significant radiochemical impurities. — NCATS
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1997 (NCT00002981)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
[11CH3]SCC[C@H](N)C(O)=O- Mol. weight
- 148.212 g/mol
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSED857BWP29 ↗
Also known as
- c11 methionine
- methionine c11
- methionine c11
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05608395 | Phase 2 | Dec 4, 2020 | Masaryk University |
| NCT03346954 | N/A | Dec 1, 2017 | University of Lyon |
| NCT02646085 | Phase 1 | Jul 1, 2016 | Harvard University |
| NCT00002981 | N/A | Jan 1, 1997 | Cornell University, National Cancer Institute (NCI) |
| NCT05511714 | N/A | — | St. Jude Children's Hospital |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Masaryk University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1997 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 1 | 1 | — |
| University of Lyon | Academic/Hospital | 1 | 1 | 1 | 2017 |
6 organizations
Page 1 / 1